Breaking News, Collaborations & Alliances

Otsuka, ShapeTX Collaborate on AAV Gene Therapies for Ocular Diseases

Will apply Shape’s AAVid capsid discovery platform and transgene engineering technology with Otsuka’s expertise in genetic payload design and ophthalmology.

Otsuka Pharmaceutical Co., Ltd. and Shape, a programmable medicine company using AI and RNA to target genetic diseases, partnered to develop intravitreally delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional targets and tissue types. The companies will apply Shape’s AAVid capsid discovery platform and transgene engineering technology with Otsuka’s expertise in genetic payload design and ophthalmology to develop novel treatments for serious eye diseases. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters